Solara Active Pharma Sciences Ltd. AI Stock Analysis
Want to see IN:SOLARA full AI Analyst Report?
Solara Active Pharma Sciences Ltd. (SOLARA) AI Stock Analysis
Solara Active Pharma Sciences Ltd.
(NSE:SOLARA)
The overall score is constrained by very weak fundamentals. The company's financial performance and valuation are both scored at the minimum of 37, driven by persistent net losses, volatile cash flows, and a negative P/E ratio. These significant risks are partially offset by strong technical momentum, with the stock trading above all key moving averages and showing bullish MACD and RSI signals. The balance sheet's moderate leverage provides a slight cushion, but the core issue of unprofitability remains the dominant factor.
Solara Active Pharma Sciences Ltd. (SOLARA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 30.96B
- Dividend Yield
- ―
- Average Volume (3M)
- 27.48K
- Price to Earnings (P/E)
- 84.3
- Beta (1Y)
- 0.69
- Revenue Growth
- 27.30%
- EPS Growth
- 456.80%
- Country
- India
- Employees
- 1,669
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Solara Active Pharma Sciences Ltd. Business Overview & Revenue Model
Company Description
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, pr...
How the Company Makes Money
Solara makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) to pharmaceutical companies that formulate and commercialize finished drug products. Revenue is generated from (1) API sales, where Solara supplies spe...
Solara Active Pharma Sciences Ltd. Financial Statement Overview
Summary
Financial performance is weak. The Income Statement (Score 28) shows persistent net losses and volatile margins, the Cash Flow Statement (Score 26) reveals inconsistent and declining cash generation with low debt coverage, and the Balance Sheet (Score 42) is the only relative bright spot with manageable leverage. The overall financial health is poor, driven by a lack of consistent profitability and weak cash flows.
Income Statement
28NegativeBalance Sheet
42NeutralCash Flow
26Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.35B | 13.69B | 12.84B | 12.89B | 14.27B | 12.68B |
| Gross Profit | 4.12B | 3.66B | 6.57B | -1.30B | 1.25B | 5.60B |
| EBITDA | 2.35B | 1.87B | 2.06B | -2.82B | 1.53B | 863.30M |
| Net Income | 369.40M | -74.10M | 5.40M | -5.67B | -221.70M | -581.50M |
Balance Sheet | ||||||
| Total Assets | 24.54B | 23.33B | 22.32B | 23.51B | 28.99B | 29.53B |
| Cash, Cash Equivalents and Short-Term Investments | 709.10M | 533.40M | 41.10M | 84.40M | 87.30M | 463.80M |
| Total Debt | 5.91B | 6.87B | 7.96B | 10.12B | 10.13B | 10.37B |
| Total Liabilities | 10.15B | 10.77B | 11.35B | 14.14B | 13.97B | 14.18B |
| Stockholders Equity | 14.36B | 12.53B | 10.94B | 9.34B | 15.00B | 15.25B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 88.80M | 1.73B | 678.10M | 449.40M | -4.51B |
| Operating Cash Flow | 0 | 617.00M | 2.13B | 1.09B | 1.56B | -2.42B |
| Investing Cash Flow | 0 | -998.60M | -368.30M | -35.10M | -811.40M | -2.43B |
| Financing Cash Flow | 0 | 386.90M | -1.80B | -1.06B | -1.13B | 3.34B |
Solara Active Pharma Sciences Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SOLARA, the sentiment is Neutral. The current price of 639.30 is below the 20-day moving average (MA) of 645.62, below the 50-day MA of 678.43, and above the 200-day MA of 561.67, indicating a neutral trend. The MACD of -0.91 indicates Negative momentum. The RSI at 48.86 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SOLARA.
Solara Active Pharma Sciences Ltd. Peers Comparison
Overall Rating
IN:STAR77Outperform
IN:IOLCP72Outperform
IN:GRANULES59Neutral
IN:HIKAL57Neutral
IN:UNICHEMLAB51Neutral
IN:SOLARA50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | INR 88.32B | 14.32 | ― | 0.52% | 11.28% | 55.18% | |
| 72Outperform | INR 55.74B | 27.42 | ― | 0.53% | 26.76% | 75.41% | |
| 59Neutral | INR 202.31B | 27.59 | ― | 0.22% | 21.75% | 36.70% | |
| 57Neutral | INR 27.54B | -557.88 | ― | 0.27% | 8.93% | -149.51% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | INR 34.01B | 9.95 | ― | ― | 6.44% | 283.10% | |
| 50Neutral | INR 32.01B | 84.26 | ― | ― | 27.30% | 456.80% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SOLARA | Solara Active Pharma Sciences Ltd. | 639.30 | 93.10 | 17.05% | |
| IN:GRANULES | Granules India Limited | 804.40 | 262.08 | 48.33% | |
| IN:HIKAL | Hikal Limited | 221.85 | -2.66 | -1.19% | |
| IN:IOLCP | IOL Chemicals & Pharmaceuticals Ltd. | 191.70 | 102.60 | 115.15% | |
| IN:STAR | Strides Pharma Science Ltd | 972.65 | 82.27 | 9.24% | |
| IN:UNICHEMLAB | Unichem Laboratories Limited | 480.05 | 12.25 | 2.62% |
Solara Active Pharma Sciences Ltd. Corporate Events
Solara Tightens KYC Norms for Physical Shareholders Under SEBI Mandate
Solara Active Pharma Sciences Ltd., a listed pharmaceutical company specializing in active pharmaceutical ingredients, is tightening compliance for investors who still hold shares in physical form. The move reflects broader regulatory efforts in Indi...
Solara Active Pharma Files Sustainability Report for FY 2025-26
Solara Active Pharma Sciences Limited has submitted its Business Responsibility and Sustainability Report for the 2025-26 financial year, covering operations from April 1, 2025 to March 31, 2026. The report is filed under SEBI’s listing regulations a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 08, 2026
